About this episode
Another in our series of Themed Podcasts focussing on GU Oncology in China. We are joined by our China Editor, Dr Yao Zhu (Fudan University, Shanghai), and Prof Xuedong Wei (Soochow University, Jiangsu). to find out what the current treatment landscape is for mHSPC in China. Is it ADT/ARPI doublets for all?? Anyone still give chemo? Who gets a PSMA PET/CT? And what is the current status and role for radioligand therapy at progression? Plus, when are we taking GU Cast to Chin again?! All this and more!
With your usual hosts, Renu Eapen and Declan Murphy
Thanks to our Gold Partner, Bayer China, for supporting our China Themed Episode Series, and for supporting all our GU Cast Conference Highlights.
Even better on our YouTube channel
Get every episode summarized
Each time GU Cast | Urology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from GU Cast | Urology Podcast
Is Copper the new Gold??! Co-PSMA trial in European Urology
GU Cast | Urology Podcast
EAU Prostate Cancer Guideline Update
GU Cast | Urology Podcast
Journal club #7 | proPSMA and Penile Fractures(!)
GU Cast | Urology Podcast
ASPIRE-ing to answer the Triplet question! With Rana McKay and Deepak Kilari
GU Cast | Urology Podcast